A new era for small molecule screening: from new targets, such as JAK2 V617F, to complex cellular screens
- PMID: 19183237
- PMCID: PMC3823349
- DOI: 10.1111/j.1582-4934.2008.00666.x
A new era for small molecule screening: from new targets, such as JAK2 V617F, to complex cellular screens
Abstract
Traditionally reserved to research and development in pharmaceutical companies, screening of small molecule libraries is rapidly becoming an approach undertaken by academic laboratories. Novel cellular assays, sensitive systems to probe function, emerging new molecular targets are just some of the reasons explaining this shift. Targets of small molecules identified in cellular screens begin to be amenable to identification by elegant genetic approaches, such as probing toxicity of candidate small molecules on libraries of genetically modified yeast strains. Several new targets, such as JAK2 V617F, an activated JAK2 (Janus Kinase 2) mutant genetically associated with the majority of human myeloproliferative neoplasms, are being actively pursued. In this Review Series, we will learn how libraries of small molecules are harnessed to identify novel molecules, that alone or in combination, have the ability to alter cell fate, cell signalling, gene expression or response to extracellular cues.
Similar articles
-
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.Blood. 2012 May 17;119(20):4625-35. doi: 10.1182/blood-2011-08-372524. Epub 2012 Feb 29. Blood. 2012. PMID: 22378845
-
MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.Diagn Mol Pathol. 2011 Mar;20(1):34-9. doi: 10.1097/PDM.0b013e3181ecd261. Diagn Mol Pathol. 2011. PMID: 21326037
-
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.Am J Hematol. 2012 Jul;87(7):746-7. doi: 10.1002/ajh.23229. Epub 2012 May 6. Am J Hematol. 2012. PMID: 22565617
-
JAK2, the JAK2 V617F mutant and cytokine receptors.Pathol Biol (Paris). 2007 Mar;55(2):88-91. doi: 10.1016/j.patbio.2006.06.003. Epub 2006 Aug 14. Pathol Biol (Paris). 2007. PMID: 16904848 Review.
-
JAK2 activation in myeloproliferative neoplasms: a potential role for heterodimeric receptors.Cell Cycle. 2008 Mar 15;7(6):714-9. doi: 10.4161/cc.7.6.5567. Epub 2008 Jan 14. Cell Cycle. 2008. PMID: 18245948 Review.
Cited by
-
Therapeutic potential of JAK2 inhibitors.Hematology Am Soc Hematol Educ Program. 2009:636-42. doi: 10.1182/asheducation-2009.1.636. Hematology Am Soc Hematol Educ Program. 2009. PMID: 20008249 Free PMC article. Review.
-
JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies.Front Cell Dev Biol. 2022 Jul 12;10:942053. doi: 10.3389/fcell.2022.942053. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35903543 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous